These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39278093)

  • 1. Immune escape between endoplasmic reticulum stress-related cancer cells and exhausted CD8+T cells leads to neoadjuvant chemotherapy resistance in ovarian cancer.
    Zhang S; Zhang Y; Song X; Wang X; Quan L; Xu P; Zhao L; Song W; Liu Q; Zhou X
    Biochem Biophys Res Commun; 2024 Nov; 733():150686. PubMed ID: 39278093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.
    van Baal JOAM; Lok CAR; Jordanova ES; Horlings H; van Driel WJ; Amant FC; Van de Vijver KK
    Virchows Arch; 2020 Oct; 477(4):535-544. PubMed ID: 32179982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma.
    Böhm S; Montfort A; Pearce OM; Topping J; Chakravarty P; Everitt GL; Clear A; McDermott JR; Ennis D; Dowe T; Fitzpatrick A; Brockbank EC; Lawrence AC; Jeyarajah A; Faruqi AZ; McNeish IA; Singh N; Lockley M; Balkwill FR
    Clin Cancer Res; 2016 Jun; 22(12):3025-36. PubMed ID: 27306793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy.
    Yaniz-Galende E; Zeng Q; Bejar-Grau JF; Klein C; Blanc-Durand F; Le Formal A; Pujade-Lauraine E; Chardin L; Edmond E; Marty V; Ray-Coquard I; Joly F; Ferron G; Pautier P; Berton-Rigaud D; Lortholary A; Dohollou N; Desauw C; Fabbro M; Malaurie E; Bonichon-Lamaichhane N; Bello Roufai D; Gantzer J; Rouleau E; Genestie C; Leary A
    Clin Cancer Res; 2024 Jul; 30(13):2790-2800. PubMed ID: 38669064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor immune microenvironment changes are associated with response to neoadjuvant chemotherapy and long-term survival benefits in advanced epithelial ovarian cancer: A pilot study.
    Cao G; Hua D; Li J; Zhang X; Zhang Z; Zhang B; Bei T; Cui L; Chen S; Wang S; Zhu L
    Front Immunol; 2023; 14():1022942. PubMed ID: 36993949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy induces phenotypic mast cell changes in high grade serous ovarian cancer.
    McAdams J; Ebott J; Jansen C; Kim C; Maiz D; Ou J; Hanley LC; Cruz P; James NE
    J Ovarian Res; 2024 Sep; 17(1):192. PubMed ID: 39342316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
    Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
    APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Impact of Tumor-Infiltrating Immune Cells on Efficacy of Neoadjuvant Chemotherapy in Patients with Advanced or Metastatic Ovarian Cancer: A Retrospective Study.
    Rao Q; Huang M; Guan M; Liu C; Wang L; Lin Z; Chen Q
    Med Sci Monit; 2024 Jul; 30():e943170. PubMed ID: 39018268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
    Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
    Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors.
    Luo Y; Xia Y; Liu D; Li X; Li H; Liu J; Zhou D; Dong Y; Li X; Qian Y; Xu C; Tao K; Li G; Pan W; Zhong Q; Liu X; Xu S; Wang Z; Liu R; Zhang W; Shan W; Fang T; Wang S; Peng Z; Jin P; Jin N; Shi S; Chen Y; Wang M; Jiao X; Luo M; Gong W; Wang Y; Yao Y; Zhao Y; Huang X; Ji X; He Z; Zhao G; Liu R; Wu M; Chen G; Hong L; ; Ma D; Fang Y; Liang H; Gao Q
    Cell; 2024 Sep; 187(18):4905-4925.e24. PubMed ID: 38971151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-grade serous ovarian cancer development and anti-PD-1 resistance is driven by IRE1α activity in neutrophils.
    Emmanuelli A; Salvagno C; Hwang SM; Awasthi D; Sandoval TA; Chae CS; Cheong JG; Tan C; Iwawaki T; Cubillos-Ruiz JR
    Oncoimmunology; 2024; 13(1):2411070. PubMed ID: 39364290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathways.
    James NE; Woodman M; De La Cruz P; Eurich K; Ozsoy MA; Schorl C; Hanley LC; Ribeiro JR
    Front Immunol; 2022; 13():965331. PubMed ID: 36131935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.
    Le Saux O; Ardin M; Berthet J; Barrin S; Bourhis M; Cinier J; Lounici Y; Treilleux I; Just PA; Bataillon G; Savoye AM; Mouret-Reynier MA; Coquan E; Derbel O; Jeay L; Bouizaguen S; Labidi-Galy I; Tabone-Eglinger S; Ferrari A; Thomas E; Ménétrier-Caux C; Tartour E; Galy-Fauroux I; Stern MH; Terme M; Caux C; Dubois B; Ray-Coquard I
    Nat Commun; 2024 Jul; 15(1):5932. PubMed ID: 39013886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological Insights into Chemotherapy Resistance in Ovarian Cancer.
    Glasgow MA; Argenta P; Abrahante JE; Shetty M; Talukdar S; Croonquist PA; Khalifa MA; Starr TK
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31052165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.
    Liang Y; Lü W; Zhang X; Lü B
    Diagn Pathol; 2018 Nov; 13(1):93. PubMed ID: 30474571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Neoadjuvant Chemotherapy on Ovarian Cancer Tumor Microenvironment: A Systematic Review of the Literature.
    Spagnol G; Ghisoni E; Morotti M; De Tommasi O; Marchetti M; Bigardi S; Tuninetti V; Tasca G; Noventa M; Saccardi C; Tozzi R; Dangaj Laniti D
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B cells critical for outcome in high grade serous ovarian carcinoma.
    Vledder A; Paijens ST; Loiero D; Maagdenberg A; Duiker EW; Bart J; Hendriks AM; Jalving M; Werner N; van Rooij N; Plat A; Wisman GBA; Yigit R; Roelofsen T; Kruse AJ; de Lange NM; Koelzer VH; de Bruyn M; Nijman HW
    Int J Cancer; 2024 Dec; 155(12):2265-2276. PubMed ID: 39175107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer.
    Leary A; Genestie C; Blanc-Durand F; Gouy S; Dunant A; Maulard A; Drusch F; Cheaib B; Michels J; Bentivegna E; LeFormal A; Mesnage S; Morice P; Pautier P; Khairallah AS
    Cancer Immunol Immunother; 2021 Feb; 70(2):519-531. PubMed ID: 32852603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial.
    Graeser M; Feuerhake F; Gluz O; Volk V; Hauptmann M; Jozwiak K; Christgen M; Kuemmel S; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kolberg-Liedtke C; Kates R; Wuerstlein R; Nitz U; Kreipe HH; Harbeck N
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.